TABLE 5.
Formation of cleavable complexes with bacterial and human topoisomerases
| Species | DNA topo- isomerase | Concn (μg/ml) for inhibition of cleavable complex formationa
|
||
|---|---|---|---|---|
| ABT-492 | Trovafloxacin | Ciprofloxacin | ||
| E. coli | DNA gyrase | 0.8 | 0.43 | 0.24 |
| Topoisomerase IV | 1.1 | 4.5 | 1.8 | |
| S. aureus | DNA gyrase | 0.57 | 1.6 | 3.5 |
| Topoisomerase IV | 1.7 | 0.19 | 0.18 | |
| Human | Topoisomerase II | >100 | >100 | >100 |
a
For bacterial topoisomerases, the results are reported as the drug concentration causing half-maximal DNA cleavage. For human topoisomerase II, the results are reported as the drug concentration causing 7% more DNA cleavage than that seen without drug treatment.